Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P22314: Variant p.Met41Thr

Ubiquitin-like modifier-activating enzyme 1
Gene: UBA1
Feedback?
Variant information Variant position: help 41 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Methionine (M) to Threonine (T) at position 41 (M41T, p.Met41Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (M) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In VEXAS; somatic mutation; the underlying nucleotide substitution affects normal alternative translation initiation and leads to aberrant initiation from M-67 to produce a shorter protein with strongly reduced enzymatic activity. Any additional useful information about the variant.


Sequence information Variant position: help 41 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1058 The length of the canonical sequence.
Location on the sequence: help SNCSPAQSVLSEVPSVPTNG M AKNGSEADIDEGLYSRQLYV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         SNCSPAQSVLSEVPSVPTNGMAKNGSEAD-IDEGLYSRQLYV

Mouse                         SNCSPAQSALSEVSSVPTNGMAKNGSEAD-IDESLYSRQLY

Rat                           SNCSSAQSVLSEVSSVPTNGMAKNGSEAD-IDESLYSRQLY

Bovine                        SNCSPAHSVLSEVPSVPANGMAKNVSDAD-IDEGLYSRQLY

Rabbit                        SNCSPAQSVLPQVPSAPTNGMAKNGSEAD-IDEGLYSRQLY

Slime mold                    --------------------------EPK-IDDALYSRQLY

Baker's yeast                 -----------------NSGLSAAG---E-IDESLYSRQLY

Fission yeast                 ----------------MSNNMNIDQTDQNTIDEGLYSRQLY

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 1058 Ubiquitin-like modifier-activating enzyme 1
Region 1 – 47 Disordered
Compositional bias 20 – 42 Polar residues
Modified residue 21 – 21 Phosphoserine
Modified residue 24 – 24 Phosphoserine
Modified residue 46 – 46 Phosphoserine
Modified residue 55 – 55 Phosphotyrosine
Mutagenesis 1 – 66 Missing. Localizes to the cytoplasm.
Mutagenesis 41 – 41 M -> A. Localizes to the nucleus; when associated with A-67.



Literature citations
Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.
Beck D.B.; Ferrada M.A.; Sikora K.A.; Ombrello A.K.; Collins J.C.; Pei W.; Balanda N.; Ross D.L.; Ospina Cardona D.; Wu Z.; Patel B.; Manthiram K.; Groarke E.M.; Gutierrez-Rodrigues F.; Hoffmann P.; Rosenzweig S.; Nakabo S.; Dillon L.W.; Hourigan C.S.; Tsai W.L.; Gupta S.; Carmona-Rivera C.; Asmar A.J.; Xu L.; Oda H.; Goodspeed W.; Barron K.S.; Nehrebecky M.; Jones A.; Laird R.S.; Deuitch N.; Rowczenio D.; Rominger E.; Wells K.V.; Lee C.R.; Wang W.; Trick M.; Mullikin J.; Wigerblad G.; Brooks S.; Dell'Orso S.; Deng Z.; Chae J.J.; Dulau-Florea A.; Malicdan M.C.V.; Novacic D.; Colbert R.A.; Kaplan M.J.; Gadina M.; Savic S.; Lachmann H.J.; Abu-Asab M.; Solomon B.D.; Retterer K.; Gahl W.A.; Burgess S.M.; Aksentijevich I.; Young N.S.; Calvo K.R.; Werner A.; Kastner D.L.; Grayson P.C.;
N. Engl. J. Med. 383:2628-2638(2020)
Cited for: INVOLVEMENT IN VEXAS; VARIANTS VEXAS LEU-41; THR-41 AND VAL-41; CHARACTERIZATION OF VARIANT VEXAS VAL-41; FUNCTION; SUBCELLULAR LOCATION; MUTAGENESIS OF 1-MET--ALA-66; 1-MET--GLY-40; MET-41 AND MET-67;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.